FRC
FRC Logo
Community
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years
Rate us on TrustpilotLeave a review

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us
  • Leave a Review

Resources

  • Videos
  • Research Reports
  • Community
  • FAQ
  • How to use the site

Browse

  • Stock Directory
  • Stock Screener
  • Market Intel Weekly
  • Report Archive

Trackers

  • Congress Trading
  • Senate Trading
  • Congress Net Worth
  • Markets

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Strategies
Intel
Analysis
Community
Company ProfileAlgernon Pharmaceuticals Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AGNPF
Algernon Pharmaceuticals Inc. Stock AnalysisComprehensive stock analysis for Algernon Pharmaceuticals Inc. (AGNPF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisAGNPF
AGNPF
Algernon Pharmaceuticals Inc.
  • Company Overview
  • Financial Data
  • Peer Comparison
  • Ownership & News
  • Discussion
AGNPF
  1. Home
  2. Stocks
  3. Algernon Pharmaceuticals Inc.

Algernon Pharmaceuticals Inc.

🇺🇸AGNPF•OTC

Algernon Pharmaceuticals Inc.

🇺🇸AGNPF•OTC
Market cap
$1.09M

Your view on AGNPF

Mkt Cap
$1.09M
Your view
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Algernon Pharmaceuticals Inc.

Industry
Biotechnology
Sector
Healthcare
CEO
Christopher J. Moreau
Headquarters
700 West Pender Street, Vancouver, BC, CA
Industry
Biotechnology
Sector
Healthcare
CEO
Christopher J. Moreau
Headquarters
700 West Pender Street, Vancouver, BC, CA
Description

Algernon Pharmaceuticals Inc. operates as a clinical stage pharmaceutical development company. It focuses on the areas of non–alcoholic steatohepatitis, chronic kidney disease, inflammatory bowel disease, idiopathic pulmonary fibrosis, chronic cough, and acute lung injury associated with COVID-19 in Canada and Australia.

The company's lead candidate is NP-120, an N-methyl-d-aspartate (NMDA) receptor glutamate receptor antagonist, which targets NMDA-type subunit 2B (Glu2NB), as well as exhibits agonist activity for the Sigma-1 receptor, a chaperone protein up-regulated during endoplasmic reticulum stress.

It is also developing AP-188, a psychedelic compound that is part of the tryptamine family for the treatment of ischemic stroke in humans. Algernon Pharmaceuticals Inc. has an agreement with Charles River Laboratories for preclinical studies of AP-188 for the company's stroke clinical research program.

Algernon Pharmaceuticals Inc. was incorporated in 2015 and is headquartered in Vancouver, Canada.

Financial Data

Stock Data

Price chart, volume, and trading data.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

About this section

Valuation, profitability, liquidity and leverage ratios for Algernon Pharmaceuticals Inc.. Starting points for Algernon Pharmaceuticals Inc.: EPS -$0.36, beta 1.25 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

About this section

Dividend history, yield and payout sustainability for Algernon Pharmaceuticals Inc.. Algernon Pharmaceuticals Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

About this section

Reported vs. expected earnings history for Algernon Pharmaceuticals Inc.. Trailing twelve-month EPS for Algernon Pharmaceuticals Inc. stands at -$0.36. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.

Financial Statements

Income statement, balance sheet, and cash flow statements.

About this section

Income statement, balance sheet and cash flow history for Algernon Pharmaceuticals Inc.. Algernon Pharmaceuticals Inc. has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.

Peer Comparison

Comparables

List of peer companies in the same industry.

Peers, the industry, and the funds that hold AGNPF12 companies
More Biotechnology companies
TickerTypeCompanySectorExchangeMkt cap
NBTXNanobiotix S.A.HealthcareNASDAQ$1.2B
NC6.AXNanollose LimitedHealthcareASX—
NCELNewcelX Ltd.HealthcareNASDAQ$1.1M
NCNANuCana plcHealthcareNASDAQ$4.6M
NDTPNDT Pharmaceuticals Inc.HealthcareOTC$143.2M
NERVMinerva Neurosciences, Inc.HealthcareNASDAQ$99.7M
NEU.AXNeuren Pharmaceuticals LimitedHealthcareASX—
NEUPNeuphoria Therapeutics Inc.HealthcareNASDAQ$12.7M
NGNENeurogene Inc.HealthcareNASDAQ$350.0M
NICXFNicox S.A.HealthcareOTC$30.9M
NIKINiki BioSolutions, Inc.HealthcareNASDAQ$127,856
NKGNNKGen Biotech, Inc. Common StockHealthcareOTC$2.6M
Ownership & News

News

Latest headlines and market coverage.

About this section

Latest headlines and company announcements for Algernon Pharmaceuticals Inc.. Coverage tracks Algernon Pharmaceuticals Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Discussion

Comments

Comments and replies from FRC members about this company.

No comments yet

Be the first to ask a question or say what you make of Algernon Pharmaceuticals Inc.

AGNPF AnalysisWeak
Past
1
Growth
2
Health
0
Profit
1
Value
0